Olema Pharmaceuticals (OLMA) Insider Horning Buys 29,500 Shares
Sandra Horning purchased 29,500 shares of OLMA on June 18, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Sandra Horning bought 29,500 shares of Olema Pharmaceuticals, Inc. ($OLMA) on June 18, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $OLMA is up 20.2% after 1 week, up 19.4% after 1 month and down 30.8% to date (from the $9.51 close on Jun 18, 2026).
OLMA
Olema Pharmaceuticals, Inc.
Key Points
- Sandra Horning bought 29,500 shares of OLMA on June 18, 2026, alongside other insiders like Graham Walmsley and Yi Larson.
- Shares of OLMA traded near $10.00 on Wednesday, with significant institutional activity including FMR LLC doubling its holdings.
- Analysts maintain a positive outlook, with Guggenheim and Jefferies setting price targets of $35 and $40, respectively.
Get $OLMA trade alerts by text
We text you when insiders, Congress or big funds trade $OLMA. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Olema Pharmaceuticals, Inc. alert may contain errors. Disclosures
Sandra Horning made a notable move by purchasing 29,500 shares of OLMA on June 18, 2026. This insider transaction was part of a series of buys by several insiders on the same day.
Insider Buying and Selling at Olema Pharmaceuticals, Inc.
On June 18, 2026, several insiders, including Sandra Horning, Graham Walmsley, Yi Larson, Andrew Rappaport, Gorjan Hrustanovic, and Ian Clark, each bought 29,500 shares of OLMA. These transactions were not made under any pre-planned trading program.
Other Institutional Activity in OLMA
FMR LLC significantly increased its stake in OLMA, adding 5,363,753 shares to hold a total of 10,386,845 shares valued at approximately $154.9 million, reflecting a 106.8% increase. Paradigm Biocapital Advisors LP also grew its holdings by 476,404 shares, resulting in 8,020,576 shares worth about $119.6 million, a 6.3% increase. Bain Capital Life Sciences Investors, LLC, however, reduced its position by 1,035,403 shares, ending with 7,473,238 shares valued at $111.4 million, marking a 12.2% decrease. Janus Henderson Group PLC added 398,294 shares, while BlackRock, Inc. increased its holdings slightly by 88,875 shares.
Olema Pharmaceuticals, Inc. Stock Up 1.8%
Shares of OLMA traded near $10.00 on Wednesday. The stock has seen significant interest from institutional investors, as reflected in recent trading activities. OLMA's market performance is underpinned by these institutional moves and insider buys, indicating a closely watched stock.
Analysts Set New Price Targets
Analysts have been bullish on OLMA. On May 13, 2026, Guggenheim maintained its "buy" rating with a $35 price target. Earlier, Jefferies assumed coverage with a "buy" rating and a $40 target on March 19, 2026. JP Morgan also maintained a "buy" rating with a $58 target on March 18, 2026. Overall, the analyst consensus remains positive, with a buy recommendation and several price targets reflecting optimism about OLMA's future performance.
Bottom Line
Sandra Horning's purchase of OLMA shares on June 18, 2026, highlights ongoing insider confidence in the company's prospects. With significant institutional interest and positive analyst ratings, OLMA remains a stock to watch. As always, remember that this information reflects past transactions and may not indicate current positions.
Related Filing Alerts
Source: Sandra Horning's Form 4 filing on $OLMA (Jun 18, 2026). Find the original filing: OLMA Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts